首页> 外国专利> Application of a Combination of a Medical Device and a Labelling Reagent in Precision Medicine Treatment for Anti-myeloma

Application of a Combination of a Medical Device and a Labelling Reagent in Precision Medicine Treatment for Anti-myeloma

机译:医疗器械和标记试剂的结合在抗骨髓瘤的精密药物治疗中的应用

摘要

#$%^&*AU2020101858A420201008.pdf#####ABSTRACT The invention provides an application of a combination of medical device and labeling reagent in precision medical treatment of anti-myeloma. The medical device is an atmospheric pressure cold plasma treatment device. The labelling reagent is used for labelling CD95 target (preferably CD95 monoclonal antibody coupled with metal nanoparticles) and guiding the atmospheric pressure cold plasma to specifically gather on the CD95 target to attack, thus causing the selective death of tumor cells. The invention defines that the target of atmospheric pressure cold plasma inducing tumor cell death is CD95, through which the function of preferentially attacking tumor cells can be realized; in particular, monoclonal antibodies can be fixed on the CD95 protein of cells according to the specific binding of antigen and antibody, and metal nanoparticles will preferentially attract the attack of plasma, which leads to target cell death.
机译:#$%^&* AU2020101858A420201008.pdf #####抽象本发明提供了医疗器械与贴标相结合的应用试剂用于抗骨髓瘤的精密医学治疗。医疗设备是常压冷等离子体处理装置。标记试剂用于标记CD95靶标(最好是CD95单克隆抗体与金属纳米颗粒偶联)和引导大气压冷等离子体专门聚集在CD95目标上攻击,从而导致肿瘤细胞的选择性死亡。本发明定义了目标大气压冷血浆诱导肿瘤细胞死亡的是CD95,通过可以实现优先攻击肿瘤细胞的功能。特别是单克隆的可以根据抗体的特异性结合将抗体固定在细胞的CD95蛋白上抗原和抗体,而金属纳米粒子将优先吸引血浆攻击,导致靶细胞死亡。

著录项

  • 公开/公告号AU2020101858A4

    专利类型

  • 公开/公告日2020-10-08

    原文格式PDF

  • 申请/专利权人 XI’AN JIAOTONG UNIVERSITY;

    申请/专利号AU20200101858

  • 申请日2020-08-17

  • 分类号C07K16/30;A61K39/395;A61K49;A61P35;H01J37/32;

  • 国家 AU

  • 入库时间 2022-08-21 11:11:34

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号